Analysis of different HER-2 mutations in breast cancer progression and drug resistance

Journal of Cellular and Molecular Medicine

Volumn 19, Issue 12, 2015, Pages 2691-2701

  Sun, Zijia ^a   Shi, Yaqin ^a   Shen, Yan ^a   Cao, Lulu ^a   Zhang, Wenwen ^a   Guan, Xiaoxiang ^a,b  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Cancer risk; HER 2; HER 2 mutation; Resistance; Variants

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; LAPATINIB; QUINAZOLINE DERIVATIVE; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MISSENSE MUTATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; BREAST NEOPLASMS; DISEASE COURSE; DRUG RESISTANCE; FEMALE; GENETICS; MUTATION; PATHOLOGY;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MUTATION; QUINAZOLINES; RECEPTOR, ERBB-2; TRASTUZUMAB;

EID: 84955185171     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12662     Document Type: Article

References (110)

1. Iqbal N, Iqbal N. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int. 2014; 2014: 852748.
2. Brandt-Rauf PW, Pincus MR, Carney WP. The c-erbB-2 protein in oncogenesis: molecular structure to molecular epidemiology. Crit Rev Oncog. 1994; 5: 313-29.
3. Telesco SE, Radhakrishnan R. Atomistic insights into regulatory mechanisms of the HER2 tyrosine kinase domain: a molecular dynamics study. Biophys J. 2009; 96: 2321-34.
4. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010; 141: 1117-34.
5. Stephens P, Hunter C, Bignell G, et al. Intragenic ERBB2 kinase mutations in tumours. Nature. 2004; 431: 525-6.
6. Yan M, Parker BA, Schwab R, et al. HER2 aberrations in cancer: implications for therapy. Cancer Treat Rev. 2014; 40: 770-80.
7. Lee JW, Soung YH, Seo SH, et al. Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin Cancer Res. 2006; 12: 57-61.
8. Sasaki H, Shimizu S, Endo K, et al. EGFR and erbB2 mutation status in Japanese lung cancer patients. Int J Cancer. 2006; 118: 180-4.
9. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008; 455: 1069-75.
10. Minami Y, Shimamura T, Shah K, et al. The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. Oncogene. 2007; 26: 5023-7.
11. Gilmer TM, Cable L, Alligood K, et al. Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib. Cancer Res. 2008; 68: 571-9.
12. Suzuki M, Shiraishi K, Yoshida A, et al. HER2 gene mutations in non-small cell lung carcinomas: concurrence with her2 gene amplification and her2 protein expression and phosphorylation. Lung Cancer. 2015; 87: 14-22.
13. De Greve J, Teugels E, Geers C, et al. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer. 2012; 76: 123-7.
14. Del Campo J, Hitt R, Sebastian P, et al. Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck. Br J Cancer. 2011; 105: 618-27.
15. Bang Y-J, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376: 687-97.
16. Lin W-L, Kuo W-H, Chen F-L, et al. Identification of the coexisting HER2 gene amplification and novel mutations in the HER2 protein-overexpressed mucinous epithelial ovarian cancer. Ann Surg Oncol. 2011; 18: 2388-94.
17. Lassus H, Sihto H, Leminen A, et al. Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J Mol Med. 2006; 84: 671-81.
18. Bekaii-Saab T, Williams N, Plass C, et al. A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma. BMC Cancer. 2006; 6: 278.
19. Tschui J, Vassella E, Bandi N, et al. Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer. Virchows Arch. 2015; 466: 1-8.
20. Kubo T, Kuroda Y, Shimizu H, et al. Resequencing and copy number analysis of the human tyrosine kinase gene family in poorly differentiated gastric cancer. Carcinogenesis. 2009; 30: bgp206.
21. Cohen EE, Lingen MW, Martin LE, et al. Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res. 2005; 11: 8105-8.
22. Arcila ME, Chaft JE, Nafa K, et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res. 2012; 18: 4910-8.
23. Bose R, Kavuri SM, Searleman AC, et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov. 2013; 3: 224-37.
24. Matthew J. Mutational analysis of breast cancer: Guiding personalized treatments. Breast. 2013; 22: S19-21.
25. Lee JW, Soung YH, Kim SY, et al. ERBB2 kinase domain mutation in the lung squamous cell carcinoma. Cancer Lett. 2006; 237: 89-94.
26. Tomizawa K, Suda K, Onozato R, et al. Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers. Lung Cancer. 2011; 74: 139-44.
27. Kelly RJ, Carter CA, Giaccone G. HER2 mutations in non-small-cell lung cancer can be continually targeted. J Clin Oncol. 2012; 30: 3318-9.
28. Shah SP, Morin RD, Khattra J, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature. 2009; 461: 809-13.
29. Shah SP, Roth A, Goya R, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012; 486: 395-9.
30. Buttitta F, Barassi F, Fresu G, et al. Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. Int J Cancer. 2006; 119: 2586-91.
31. Shigematsu H, Takahashi T, Nomura M, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res. 2005; 65: 1642-6.
32. Shimamura T, Ji H, Minami Y, et al. Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. Cancer Res. 2006; 66: 6487-91.
33. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 2129-39.
34. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010; 11: 121-8.
35. Pauletti G, Godolphin W, Press MF, et al. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. 1996; 13: 63-72.
36. Kamoshida S. Challenges of immunohistochemistry for individualized cancer chemotherapy. Rinsho Byori. 2014; 62: 710-8.
37. Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014; 32: 3744-52.
38. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344: 783-92.
39. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353: 1673-84.
40. Baselga J, Cortés J, Im S-A, et al. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J Clin Oncol. 2014; 32: 3753-61.
41. Weigelt B, Reis-Filho JS. Activating mutations in HER2: neu opportunities and neu challenges. Cancer Discov. 2013; 3: 145-7.
42. Boulbes DR, Arold ST, Chauhan GB, et al. HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer. Mol Oncol. 2014; 9: 586-600.
43. Ross JS, Wang K, Gay LM, et al. A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma. Clin Cancer Res. 2014; 20: 68-75.
44. Wang SZE, Narasanna A, Perez-Torres M, et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell. 2006; 10: 25-38.
45. Fang Y, Jiang Y, Wang X, et al. Somatic mutations of the HER2 in metastatic breast cancer. Tumour Biol. 2014; 35: 11851-4.
46. Herter-Sprie GS, Greulich H, Wong K-K. Activating mutations in ERBB2 and their impact on diagnostics and treatment. Front Oncol. 2013; 3: 86.
47. Greulich H, Kaplan B, Mertins P, et al. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci USA. 2012; 109: 14476-81.
48. Kan ZY, Jaiswal BS, Stinson J, et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature. 2010; 466: 869-U103.
49. Vornicova O, Hershkovitz D, Yablonski-Peretz T, et al. Treatment of metastatic extramammary Paget's disease associated with adnexal adenocarcinoma, with anti-HER2 drugs based on genomic alteration ERBB2 S310F. Oncologist. 2014; 19: 1006-7.
50. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474: 609-15.
51. Serra V, Vivancos A, Puente XS, et al. Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation. Cancer Discov. 2013; 3: 1238-44.
52. Yamamoto H, Higasa K, Sakaguchi M, et al. Novel germline mutation in the transmembrane domain of HER2 in familial lung adenocarcinomas. J Natl Cancer Inst. 2014; 106: djt338.
53. Parra-Palau JL, Morancho B, Peg V, et al. Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy. J Natl Cancer Inst. 2014; 106: dju291.
54. Mitra D, Brumlik MJ, Okamgba SU, et al. An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance. Mol Cancer Ther. 2009; 8: 2152-62.
55. Barić M, Kulić A, Sirotković-Skerlev M, et al. Circulating her-2/neu extracellular domain in breast cancer patients-correlation with prognosis and clinicopathological parameters including steroid receptor, her-2/neu receptor coexpression. Pathol Oncol Res. 2014; 21: 1-7.
56. Jackson C, Browell D, Gautrey H, et al. Clinical significance of HER-2 splice variants in breast cancer progression and drug resistance. Int J Cell Biol. 2013; 2013: 973584.
57. Coley HM. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev. 2008; 34: 378-90.
58. Fang L, Barekati Z, Zhang B, et al. Targeted therapy in breast cancer: what's new. Swiss Med Wkly. 2011; 141: w13231.
59. De Mattos-Arruda L, Cortes J. Advances in first-line treatment for patients with HER-2+ metastatic breast cancer. Oncologist. 2012; 17: 631-44.
60. Thery J-C, Spano J-P, Azria D, et al. Resistance to human epidermal growth factor receptor type 2-targeted therapies. Eur J Cancer. 2014; 50: 892-901.
61. Marchini C, Gabrielli F, Iezzi M, et al. The human splice variant Delta16HER2 induces rapid tumor onset in a reporter transgenic mouse. PLoS ONE. 2011; 6: e18727.
62. Castiglioni F, Tagliabue E, Campiglio M, et al. Role of exon-16-deleted HER2 in breast carcinomas. Endocr Relat Cancer. 2006; 13: 221-32.
63. Parra-Palau JL, Pedersen K, Peg V, et al. A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the down-modulation of the estrogen receptor in HER2-positive breast cancers. Cancer Res. 2010; 70: 8537-46.
64. Sperinde J, Jin X, Banerjee J, et al. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients. Clin Cancer Res. 2010; 16: 4226-35.
65. Arribas J, Baselga J, Pedersen K, et al. p95HER2 and breast cancer. Cancer Res. 2011; 71: 1515-9.
66. Tural D, Akar E, Mutlu H, et al. P95 HER2 fragments and breast cancer outcome. Expert Rev Anticancer Ther. 2014; 14: 1089-96.
67. Pedersen K, Angelini P-D, Laos S, et al. A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis. Mol Cell Biol. 2009; 29: 3319-31.
68. Sáez R, Molina MA, Ramsey EE, et al. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin Cancer Res. 2006; 12: 424-31.
69. Duchnowska R, Sperinde J, Chenna A, et al. Quantitative measurements of tumoral p95HER2 protein expression in metastatic breast cancer patients treated with trastuzumab: independent validation of the p95HER2 clinical cutoff. Clin Cancer Res. 2014; 20: 2805-13.
70. Andrade de Mello R, de Vasconcelos A, Ribeiro RA, et al. Insight into p95HER2 in breast cancer: molecular mechanisms and targeted therapies. Recent Pat DNA Gene Seq. 2012; 6: 56-63.
71. Azios NG, Romero FJ, Denton MC, et al. Expression of herstatin, an autoinhibitor of HER-2/neu, inhibits transactivation of HER-3 by HER-2 and blocks EGF activation of the EGF receptor. Oncogene. 2001; 20: 5199-209.
72. AbdRaboh NR, Shehata HH, Ahmed MB, et al. HER1 R497K and HER2 I655V polymorphisms are linked to development of breast cancer. Dis Markers. 2013; 34: 407-17.
73. Millikan RC, Hummer AJ, Wolff MS, et al. HER2 codon 655 polymorphism and breast cancer: results from kin-cohort and case-control analyses. Breast Cancer Res Treat. 2005; 89: 309-12.
74. Xie D, Shu X-O, Deng Z, et al. Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst. 2000; 92: 412-7.
75. Lu S, Wang Z, Liu H, et al. HER2 Ile655Val polymorphism contributes to breast cancer risk: evidence from 27 case-control studies. Breast Cancer Res Treat. 2010; 124: 771-8.
76. Ma Y, Yang J, Zhang P, et al. Lack of association between HER2 codon 655 polymorphism and breast cancer susceptibility: meta-analysis of 22 studies involving 19, 341 subjects. Breast Cancer Res Treat. 2011; 125: 237-41.
77. Chen W, Yang H, Tang WR, et al. Updated meta-analysis on HER2 polymorphisms and risk of breast cancer: evidence from 32 studies. Asian Pac J Cancer Prev. 2014; 15: 9643-7.
78. Rutter JL, Chatterjee N, Wacholder S, et al. The HER2 I655V polymorphism and breast cancer risk in ashkenazim. Epidemiology. 2003; 14: 694-700.
79. Millikan R, Eaton A, Worley K, et al. HER2 codon 655 polymorphism and risk of breast cancer in African Americans and whites. Breast Cancer Res Treat. 2003; 79: 355-64.
80. Kruszyna L, Lianeri M, Roszak A, et al. HER2 codon 655 polymorphism is associated with advanced uterine cervical carcinoma. Clin Biochem. 2010; 43: 545-8.
81. Frank B, Hemminki K, Wirtenberger M, et al. The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk. Carcinogenesis. 2005; 26: 643-7.
82. Tai W, Mahato R, Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J Controlled Release. 2010; 146: 264-75.
83. Kümler I, Tuxen MK, Nielsen DL. A systematic review of dual targeting in HER2-positive breast cancer. Cancer Treat Rev. 2014; 40: 259-70.
84. GrausPorta D, Beerli RR, Daly JM, et al. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 1997; 16: 1647-55.
85. Alimandi M, Romano A, Curia MC, et al. Cooperative signaling of Erbb3 and Erbb2 in neoplastic transformation and human mammary carcinomas. Oncogene. 1995; 10: 1813-21.
86. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001; 2: 127-37.
87. Holbro T, Beerli RR, Maurer F, et al. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA. 2003; 100: 8933-8.
88. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 2006; 7: 505-16.
89. Slattery ML, John EM, Stern MC, et al. Associations with growth factor genes (FGF1, FGF2, PDGFB, FGFR2, NRG2, EGF, ERBB2) with breast cancer risk and survival: the Breast Cancer Health Disparities Study. Breast Cancer Res Treat. 2013; 140: 587-601.
90. Slamon DJ, Clark GM, Wong SG, et al. Human-breast cancer - correlation of relapse and survival with amplification of the her-2 neu oncogene. Science. 1987; 235: 177-82.
91. Nielsen DL, Andersson M, Kamby C. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Cancer Treat Rev. 2009; 35: 121-36.
92. Chen FL, Xia W, Spector NL. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors. Clin Cancer Res. 2008; 14: 6730-4.
93. Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2009; 27: 5838-47.
94. Tortora G. Mechanisms of resistance to HER2 target therapy. J Natl Cancer Inst Monogr. 2011; 2011: 95-8.
95. Rexer BN, Arteaga CL. Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Crit Rev Oncog. 2012; 17: 1-16.
96. Wu JY, Yu CJ, Chang YC, et al. Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res. 2011; 17: 3812-21.
97. Rexer BN, Ghosh R, Narasanna A, et al. Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2. Clin Cancer Res. 2013; 19: 5390-401.
98. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005; 2: 225-35.
99. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002; 2: 117-25.
100. Antonescu CR, Besmer P, Guo TH, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res. 2005; 11: 4182-90.
101. Trowe T, Boukouvala S, Calkins K, et al. EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation. Clin Cancer Res. 2008; 14: 2465-75.
102. Li G, Wang X, Hibshoosh H, et al. Modulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 mutations and PHLDA1. PLoS ONE. 2014; 9: e106349.
103. Kancha RK, von Bubnoff N, Bartosch N, et al. Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib. PLoS ONE. 2011; 6: e26760.
104. Piechocki MP, Yoo GH, Dibbley SK, et al. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu. Cancer Res. 2007; 67: 6825-43.
105. Wang SE, Yu Y, Criswell TL, et al. Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediators. Oncogene. 2010; 29: 3335-48.
106. Falchook GS, Janku F, Tsao AS, et al. Non-small-cell lung cancer with HER2 exon 20 mutation regression with dual HER2 inhibition and anti-VEGF combination treatment. J Thorac Oncol. 2013; 8: E19-20.
107. Perera SA, Li D, Shimamura T, et al. HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc Natl Acad Sci USA. 2009; 106: 474-9.
108. Mazieres J, Peters S, Lepage B, et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol. 2013; 31: 1997-U307.
109. Cappuzzo F, Bemis L, Varella-Garcia M. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N Engl J Med. 2006; 354: 2619-21.
110. Endo Y, Dong Y, Yoshimoto N, et al. HER2 mutation status in Japanese HER2-negative breast cancer patients. Jpn J Clin Oncol. 2014; 44: 619-23.